Company intelligence / Profile preview
Trajectum Pharma
Utrecht, Netherlandstrajectumpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Trajectum Pharma develops novel immunotherapies targeting autoimmune diseases. Its lead program uses ex vivo modified autologous dendritic cells loaded with a proprietary peptide to induce immune tolerance in rheumatoid arthritis. The company’s main clinical study (“TOLERANT” trial) aims to demonstrate safety and feasibility of this approach. Early results focus on safety, immune response modulation, and reduction of disease activity; the study remains ongoing as of March 2025.
- Therapeutic areas
- Immunology
- Modalities
- mRNA-based therapiesCell therapies (tolerogenic dendritic cells)Lipid nanoparticles (for delivery)Peptide-loaded autologous dendritic cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University Medical Center Utrecht (academic collaboration/sponsor for the TOLERANT trial)
Beyond the preview
Go deeper on Trajectum Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trajectum Pharma.